Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Klazien Matter-Walstra Matthias Schwenkglenks Dirk Klingbiel |
| Publication date | June 8, 2016 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |